Bloomios, Inc. (BLMS)
| Market Cap | 6.79K |
| Revenue (ttm) | 8.23M |
| Net Income (ttm) | -39.61M |
| Shares Out | 67.87M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500,000 |
| Average Volume | 1,037,714 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.0001 - 0.0001 |
| Beta | -0.02 |
| RSI | 37.88 |
| Earnings Date | Apr 17, 2026 |
About Bloomios
Bloomios, Inc. manufactures, markets, and distributes cannabidiol products. The company’s product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. It sells its hemp derived supplements and cosmetic products through wholesale and retail distribution channels. The company was formerly known as XLR Medical Corp. and changed its name to Bloomios, Inc. in April 2021. Bloomios, Inc. was incorporated in 2001 and is headquartered in Santa Barbara, California. [Read more]
Full Company ProfileFinancial Performance
In 2022, Bloomios's revenue was $6.08 million, a decrease of -28.43% compared to the previous year's $8.49 million. Losses were -$13.77 million, 584.8% more than in 2021.
Financial StatementsNews
Bloomios Appoints Kevin Henry as National Sales Director
SANTA BARBARA, Calif. , June 9, 2023 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading innovator in contract manufacturing of hemp-derived cannabinoid & mushroom edibles, cosmetic & topical spor...
Bloomios Reports Q1 2023 Revenue up 30% Sequentially and 84% Y/Y to $2.75 Million
Annualized Run Rate Hits $11.0 Million vs. $6.1 million in 2022, Driven by Increased Order Flow and Production Capacity Q2 2023 Outlook of Revenues to Exceed $3 million, up more than 137% SANTA BARBAR...
Bloomios Appoints Industry Veteran, Joe Reid, as Chief Manufacturing Officer
SANTA BARBARA, Calif. , March 27, 2023 /PRNewswire/ -- Bloomios, Inc. (the "Company") (OTCQB: BLMS), a leading white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, ...
Bloomios Completes $23.5 Million Acquisition of Leading Gummy Manufacturer
Transaction Expected to Double Production Capacity and Supports Entry of Direct-to-Consumer Market SANTA BARBARA, Calif. , Oct. 27, 2022 /PRNewswire/ -- Bloomios, Inc. (the "Company") (OTCQB: BLMS), ...
Upexi Announces Sale of Select CBD Assets for $23.5 Million
Transaction accelerates our Amazon and DTC eCommerce brand focused strategy , strengthens balance sheet and provides additional capital flexibility to invest in further acquisitions Company reiterates...
Bloomios To Present at The 2022 LD Micro Main Event October 25-27
Santa Barbara, California--(Newsfile Corp. - October 20, 2022) - Bloomios, Inc. (OTCQB: BLMS), a leading hemp derived cannabinoid supplements and nutraceutical contract manufacturer specializing in fu...
Bloomios to Develop and Produce New Range of Private-Label Products Utilizing, Ashwagandha, Melatonin, Kratom, Lion's Mane, Valerian Root, Reishi Mushroom and other Natural Ingredients
SANTA BARBARA, Calif. , Aug. 4, 2022 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading hemp and nutraceutical manufacturer specializing in full service product development, R&D and compliance so...
Bloomios to Present at the 2022 LD Micro Invitational June 7-9
SANTA BARBARA, Calif. , May 25, 2022 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading hemp and nutraceutical manufacturer specializing in full service product development, R&D and compliance so...
Bloomios Expands Production Capacity by 300%, Setting Stage for Strong Growth in 2022
SANTA BARBARA, Calif. , May 18, 2022 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading hemp and nutraceutical manufacturer specializing in full service product development, R&D and compliance so...
Bloomios Reports 2021 Revenue at Record $8.5 Million, up from $1.3 Million in 2020
SANTA BARBARA, Calif. , April 19, 2022 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading hemp and nutraceutical manufacturer specializing in full service product development, R&D and compliance ...
Bloomios Selected as Exclusive Manufacturer for DRYWORLD's New Athletic Performance CBD Product Line
SANTA BARBARA, Calif., March 31, 2022 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading manufacturer and wholesaler of hemp-derived cannabinoid nutraceuticals and cosmetics, has been selected a...
Bloomios Engages CMA to Lead New Investor and Public Relations Campaign
SANTA BARBARA, Calif. , March 16, 2022 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading researcher, manufacturer and wholesaler of hemp-derived cannabinoid nutraceuticals and cosmetics, has eng...
Bloomios Begins Trading on OTCQB Venture Market as BLMS, as Hemp-Derived Cannabinoid Product Sales Exceed $8 million
SANTA BARBARA, Calif., March 15, 2022 /PRNewswire/ -- Bloomios, Inc. (OTCQB: BLMS), a leading researcher, manufacturer and wholesaler of hemp-derived cannabinoid nutraceuticals and cosmetics, will beg...